Table 2. Univariate analysis to determine factors associated with peak neutralizing antibody titer.
| High titer group (n = 25) | Low titer group (n = 25) | P value | |
|---|---|---|---|
| Demographic | |||
| Age, median years (interquartile range) | 57 (47–64) | 51 (29–61) | 0.065 |
| Female | 10 (40) | 12 (48) | 0.776 |
| Chronic comorbidities | |||
| Hypertension | 5 (20) | 4 (16) | 1.000 |
| Chronic heart disease | 3 (12) | 0 (0) | 0.235 |
| Chronic lung disease | 0 (0) | 2 (8) | 0.490 |
| Chronic liver disease | 1 (4) | 0 (0) | 1.000 |
| Chronic kidney disease | 0 (0) | 2 (8) | 0.490 |
| Diabetes mellitus | 5 (20) | 4 (16) | 1.000 |
| No chronic comorbidities | 13 (52) | 16 (64) | 0.567 |
| Presenting symptoms | |||
| Fever | 21 (84) | 13 (52) | 0.032 |
| Dyspnea | 5 (20) | 5 (20) | 1.000 |
| Cough | 9 (36) | 16 (64) | 0.089 |
| Rhinorrhea | 3 (12) | 5 (20) | 0.702 |
| Sore throat | 5 (20) | 5 (20) | 1.000 |
| Diarrhea | 5 (20) | 6 (24) | 1.000 |
| Blood tests on admission, median, interquartile range | |||
| Hemoglobin (g/dL) | 13.3 (12.6–14.5) | 14.0 (12.5–15.0) | 0.232 |
| Total white blood cell count (×109/L) | 5.1 (3.5–6.1) | 5.7 (4.8–6.9) | 0.135 |
| Neutrophil count (×109/L) | 3.9 (2.3–4.5) | 3.5 (2.5–4.8) | 0.613 |
| Lymphocyte count (×109/L) | 0.9 (0.7–1.5) | 1.2 (0.9–1.8) | 0.033 |
| Platelet count (×109/L) | 164 (138–243) | 199 (172–260) | 0.021 |
| Urea (mmol/L) | 4.1 (3.5–5) | 4.3 (2.9–5.0) | 0.719 |
| Creatinine (μmol/L) | 76 (64–99) | 78 (64–90) | 0.861 |
| Alanine aminotransferase (U/L) | 33 (22–46) | 23 (17–44) | 0.156 |
| Severity | |||
| Oxygen supplementation | 13 (52) | 2 (8) | 0.001 |
| ICU admission | 6 (24) | 2 (8) | 0.247 |
| Death | 0 (0) | 1 (4) | 1.000 |